An observational study in Schizophrenia, sponsored by Rene Kahn. Completed at 1 site in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Rene Kahn · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Schizophrenia with a site in Israel — 3 open to participants now, 4 under way, none of them phase 3. Schizophrenia · Israel.
Among the 112 studies in Schizophrenia with a site in Israel, this one is the 8th largest by enrollment of the 22 observational ones that give a count, is one of 2 that started in 2021, is one of 22 observational ones, and was the 103rd registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →3 of the 112 studies in Schizophrenia with a site in Israel are open now. Recruiting first, the newest first:
Amit Lotan · Sites in Israel
Ages 18–40 · Healthy volunteers
Mapi Pharma Ltd. · Sites in Israel, India
Ages 18–64
Sheba Medical Center · Sites in Israel
Ages 18+ · Healthy volunteers
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 14 · Phase 3 29 · Phase 4 15
First in 2000; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is below the median of 178 across 508 observational studies indexed under Schizophrenia.
Median enrollment 53 across the 88 interventional studies, 100 across the 22 observational. Of the 61 that completed or were terminated, 13 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 112 have an industry lead sponsor. The 10 most frequent:
Rene Kahn is the lead sponsor of 3 studies on the registry; none are open to participants now.
Rene Kahn has 2 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
1 of the studies in Schizophrenia with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 112 studies in Schizophrenia with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Schizophrenia is a chronic psychiatric illness with a heterogeneous disease course, varying from periods of symptomatic remission to relapse. Relative to the wealth of scientific data on the course of schizophrenia during the two years following the first psychotic episode, the outcome of schizophrenia patients over the first decade of their illness has been studied to a lesser degree. In this follow-up cohort study the aim is to investigate the long-term outcome of schizophrenia patients who participated in the previously conducted EULAST-I clinical trial, in the first decade after being diagnosed.
At this point, given the heterogeneity of published studies, it remains unclear if depot medication can reduce relapse rates and improve clinical outcome when offered to all patients in need of continuation treatment with antipsychotics. Before anyone can conclude whether or not all schizophrenia patients could benefit from a switch to depot formulations, several questions remain to be answered. Is depot medication associated with better continuation rates and outcome? How are depot medications tolerated as compared to oral medication? In order to clarify these important issues this study aims to perform a large multi-center trial in which schizophrenia patients in need of continuous treatment who are randomized 1:1:1:1 to two different depot preparations or to two different oral medications; patients will be followed up for a total of 19 months.
The primary objective of this trial is to compare all cause discontinuation rates in patients with schizophrenia randomized to oral antipsychotic medications (i.e., aripiprazole or paliperidone) versus depot antipsychotic medications (i.e., paliperidone palmitate or aripiprazole depot) over an 18 month follow-up period.
The study population will consist of patients with schizophrenia who participated in the previously conducted EULAST-I clinical trial. All patients who were randomized (to either aripiprazole oral, aripiprazole depot, paliperidone oral, paliperidone depot) or who participated in the naturalistic follow-up part of the EULAST-I clinical trial will be invited to participate in the current long-term follow-up cohort study (EULAST-II); this includes patients who dropped-out after randomization, patients who met All Cause Discontinuation (ACD) criteria and patients who completed the previous EULAST-I clinical trial. Patients will be over 18 years of age. The current long-term follow-up visit will take place at least three years after each patient's last visit as conducted within the EULAST-I clinical trial or the naturalistic follow-up study.
Inclusion Criteria:
Having been randomized to one of the four treatment arms (aripiprazole oral, aripiprazole depot, paliperidone oral, paliperidone depot) in the 2014-002765-30 EULAST-I clinical trial or having participated in the EULAST-I naturalistic cohort study.
Exclusion Criteria: No exclusion criteria are applicable in this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To assess which baseline EULAST-I clinical trial baseline characteristics predict healthcare utilization (defined as number of days hospitalized) over a period of 3 - 10 years (since the EULAST-I clinical trial baseline visit).
Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).
To provide insight into long-term social functioning as measured through the Personal and Social Performance (PSP) scale.
Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).
To provide insight into long-term sociodemographic outcome (living circumstances, education, marital status).
Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).
To provide insight in changes in neuropsychiatric diagnoses as measured through the Mini-International Neuropsychiatric Interview 7.0.2 (M.I.N.I. 7.0.2) since the EULAST-I clinical trial screening visit.
Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).
To provide insight in long-term outcome in quality of life as measured through the Euroqol quality of life scale (EQ-5D-5L).
Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).
To provide insight in long-term outcome in alcohol and drug use as well as smoking as measured through the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST).
Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).
To provide insight in long-term outcome of tardive dyskinesia as measured through the Abnormal and Involuntary Movement Scale (AIMS).
Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).
To provide insight in long-term outcome of extrapyramidal symptoms as measured through the St. Hans rating scale.
Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).
To provide insight in the use of antipsychotic medication and other medication since the previous EULAST-I clinical trial.
Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).
To provide insight into the reasons for hospitalizations since the baseline visit of the previous EULAST-I clinical trial.
Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).
To provide insight into the incidence of suicide attempts since the baseline visit of the previous EULAST-I clinical trial
Time frame: 3 - 10 years (since the EULAST-I clinical trial baseline visit).
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2021 to primary completion in Feb 2026, 49 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.